Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

PURPOSE: To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurable solid tumors associated with colony-stimulating factor 1 receptor (CSF1R) and/or KIT proto-oncogene receptor tyrosine kinase activity. PATIENTS AND METHODS: From this two-part phase I,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tap, William D., Singh, Arun S., Anthony, Stephen Patrick, Sterba, Mike, Zhang, Chao, Healey, John H., Chmielowski, Bartosz, Cohn, Allen Lee, Shapiro, Geoffrey I., Keedy, Vicki L., Wainberg, Zev A., Puzanov, Igor, Cote, Gregory M., Wagner, Andrew J., Braiteh, Fadi, Sherman, Eric, Hsu, Henry H., Peterfy, Charles, Gelhorn, Heather L., Ye, Xin, Severson, Paul, West, Brian L., Lin, Paul S., Tong-Starksen, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401544/
https://www.ncbi.nlm.nih.gov/pubmed/34716196
http://dx.doi.org/10.1158/1078-0432.CCR-21-2007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401544/
https://www.ncbi.nlm.nih.gov/pubmed/34716196
http://dx.doi.org/10.1158/1078-0432.CCR-21-2007

Ejemplares similares